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Abstract
Background: The blood proteome is thought to represent a rich source of biomarkers for early stage disease detection.
Nevertheless, three major challenges have hindered biomarker discovery: a) candidate biomarkers exist at extremely low
concentrations in blood; b) high abundance resident proteins such as albumin mask the rare biomarkers; c) biomarkers are
rapidly degraded by endogenous and exogenous proteinases.
Methodology and Principal Findings: Hydrogel nanoparticles created with a N-isopropylacrylamide based core (365 nm)-
shell (167 nm) and functionalized with a charged based bait (acrylic acid) were studied as a technology for addressing all
these biomarker discovery problems, in one step, in solution. These harvesting core-shell nanoparticles are designed to
simultaneously conduct size exclusion and affinity chromatography in solution. Platelet derived growth factor (PDGF), a
clinically relevant, highly labile, and very low abundance biomarker, was chosen as a model. PDGF, spiked in human serum,
was completely sequestered from its carrier protein albumin, concentrated, and fully preserved, within minutes by the
particles. Particle sequestered PDGF was fully protected from exogenously added tryptic degradation. When the
nanoparticles were added to a 1 mL dilute solution of PDGF at non detectable levels (less than 20 picograms per mL) the
concentration of the PDGF released from the polymeric matrix of the particles increased within the detection range of ELISA
and mass spectrometry. Beyond PDGF, the sequestration and protection from degradation for a series of additional very low
abundance and very labile cytokines were verified.
Conclusions and Significance: We envision the application of harvesting core-shell nanoparticles to whole blood for
concentration and immediate preservation of low abundance and labile analytes at the time of venipuncture.
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Introduction
The peptidome/metabolome, populated by small circulating
proteins, nucleic acids or metabolites, represents a valuable source
of biomarker information reflecting the biologic state of the
organism [1,2]. Measurement of circulating biomarker molecules
holds great promise as a means to a) detect early stage disease[3],
b) stratify patients into distinct risk subgroups, and c) monitor
progression or response to therapy [4]. The low-molecular-weight
(LMW) region of the blood proteome, which is a mixture of small
intact proteins and fragments of large proteins, is an emerging
arena for biomarker research [5]. Tissue-derived proteins, that are
too large to passively enter the blood stream, can be represented in
the circulation as peptides or protein fragments. This LMW region
of the proteome is particularly amenable to biomarker discovery
based approaches using current mass spectrometry technology.
Nevertheless, despite the recent progress in proteomics
discovery and measurement technologies, identification of clini-
cally useful biomarkers has been painfully slow. While this lack of
progress is partly due to the inherent analytical difficulties
associated with an extraordinarily complex sample matrix such
as blood, there are three fundamental and serious physiologic
barriers thwarting biomarker discovery and measurement:
1. The foremost problem in biomarker measurement is the
extremely low abundance (concentration) of candidate markers
in blood, which exist below the detection limits of mass
spectrometry and conventional immunoassays. Such a low
abundance would be expected for early stage disease since the
diseased tissue constitutes a small proportion of the patient’s
tissue volume. Early-stage disease detection generally provides
better overall patient outcomes.
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2. The second major problem for biomarker discovery and
measurement is the overwhelming abundance of resident
proteins such as albumin and immunoglobulins, accounting
for 90% of circulating plasma proteins, which confound and
mask the isolation of rare biomarkers [6]. In fact, the vast
majority of low abundance biomarkers are non-covalently and
endogenously associated with carrier proteins, such as albumin,
which exist in a billion fold excess compared to the rare
biomarker [7].
3. A third serious challenge for biomarker measurement is the
propensity for the low abundance biomarkers to be rapidly
degraded by endogenous and exogenous proteinases immedi-
ately after the blood sample is drawn from the patient.
Degradation of candidate biomarkers occurs also during
transportation and storage of blood, generating significant
false positive and false negative results [8].
The field of nanotechnology offers fresh approaches to address
these three fundamental physiologic barriers to biomarker
discovery. Recently, we have engineered smart hydrogel core-
shell nanoparticles that overcome these three barriers and will do
so in one step, in solution [9]. A hydrogel particle is a cross
linked particle of sub-micrometer size composed of hydrophilic
polymers capable of swelling and contracting as a result of the
application of an environmental trigger, e.g., temperature, pH,
ionic strength or electric field [10–14]. Hydrogel particles have
extensive applications in biomedicine and biotechnology [15–18]
because of their high biocompatibility and unique physiochem-
ical properties.
The nanoparticles simultaneously conduct molecular sieve
chromatography and affinity chromatography in one step in
solution [9]. The molecules captured and bound within the affinity
matrix of the particles are protected from degradation by
exogenous or endogenous proteases. Despite the promise of this
feasibility study [9], it remained to be proven whether such
hydrogel particle technology could be shown to be applicable to a
clinically relevant, highly labile, and very low abundance
biomarker. To address this challenge we created a new class of
core-shell particles and tailored the core bait to specifically capture
a model biomarker Platelet Derived Growth Factor (PDGF). In
order to study the applicability of hydrogel particles to a real world
problem, PDGF was chosen as a highly challenging model for
cancer related biomarker analysis because it is present in blood in
extremely low concentration (3 ng/mL), with a short half life
(2 minutes) [12]. The PDGFs are a family of peptide growth
factors that signal through cell surface tyrosine kinase receptors
and stimulate various cellular functions including growth,
proliferation, and differentiation. Four different polypeptide chains
(PDGF-A, -B, -C, and -D) encoded by different genes (chromo-
somes 4, 7, 11, 22) have been described [19,20]. PDGF plays a
role in angiogenesis and the level of tumor interstitial pressure
during tumor progression [21–23]. Several new therapeutic agents
designed to target PDGF and its receptor are presently in use in
the oncology clinic[24–28]. Despite this known theranostic value,
PDGF can not be measured routinely and accurately in the clinic
because of the extreme low abundance and high instability of this
low molecular weight growth factor. Beyond PDGF, the
sequestration and protection from degradation for a series of
additional very low abundance and very labile chemokines such as
CCL28, CCL24, and CXCL12 were verified. These chemokines
have a concentration in serum of 44 pg/mL [29], 103 pg/mL
[30], and 1.5 ng/mL [31], respectively. The half life of
chemokines in blood is very short, less tan ten minutes [32].
Chemokines are small cytokines that direct migration of
leukocytes, activate inflammatory responses and participate in
tumor growth. Chemokines modulate tumor behavior by three
important mechanisms: regulation of tumor-associated angiogen-
esis, activation of a host tumor-specific immunological response,
and direct stimulation of tumor cell proliferation in an autocrine
fashion. All of these mechanisms are promising drug targets [33].
The incorporation of a bait molecule in the porous latex if
hydrogel particles drives the uptake of molecules in solution, shifts
the equilibrium towards association with the particles, and assures
that captured molecules are preserved from degradation. The bait
can be introduced via copolymerization of a monomer carrying
the chemical moiety or via loading the chemical moiety with
covalent bonding to an already formed hydrogel particle.
A menu of bait chemistries has been created to selectively bind
and concentrate a diverse range of biomarkers, such as a) proteins
and peptides, b) metabolites, c) lipids and fatty acids, d) nucleic
acids, and e) post translationally modified peptides (e.g. glycosy-
lated and phosphorylated). Bait chemistries include charge-based
bait (acrylic acid, allylamine co-monomer), triazine loaded dye
(cibacron blue), beta-cyclodextrin, boronic acid. A summary of
bait chemistry we are working on is shown in Fig. 1
Acrylic acid is deprotonated at pH values greater than 3.5 and
therefore carries a negative charge that targets positively charged
polypeptides and proteins. Allylamine (pK=9.69 [34]) acts as a
bait for polypeptides and proteins that have net negative charge.
The affinity of polypeptides to charged particles has been proven
to be higher than the affinity of polypeptide for carrier proteins
and depends on the value of the isoelectric point of proteins and
the dissociation constant of particles [9]. Harvesting and
concentration properties of charged particles depend on the pH
and ionic strength of the solution.
An alternative bait strategy is to load NIPAm based particles
with triazine derived textile dyes (Cibacron blue F3G-A, Procion
red H8BN) [35]. Dyes have been used in affinity chromatography
for their low cost and highly specific molecular recognition [36].
We have successfully synthesized Cibacron Blue dye loaded
hydrogel particles and demonstrated their efficacy for uptake small
proteins and hormones from urine [37].
Additionally, cyclodextrins were coupled to hydrogel particles.
Cyclodextrins are cyclic glucose oligosaccharides that have
lipophilic inner cavities and hydrophilic outer surfaces, that are
capable of interacting with hydrophobic guest molecules to form
noncovalent complexes, and have been extensively used as vector
for drug delivery [38]. Cyclodextrin have been shown to bind
cholesterol [39], steroids [40], DOPA [41]. Hydrogen bonds, Van
der Waals interaction, electrostatic interactions are thought to be
the forces that attract and stabilize guest molecules that have
suitable size and preferably hydrophobic character [42].
Furthermore, we designed particles that contain boronic acid
groups, which are known to form complexes with diol groups of
target biomolecules. Boronate ion has been used for affinity
chromatography applications involving the selective isolation of
nucleotides, RNA, glycated proteins and glycoenzymes [43–48].
In a core-shell architecture, the bait containing region is covered
by a porous shell. Core-shell hydrogel particles are of special utility
because the properties of the core and shell can be tailored
separately to suit a particular application. In many core-shell
particle systems used for drug delivery, the core is designed to have
the properties required for its intended application [12,49–51].
The shell is then separately added to surround and shield the core.
The thickness of the shell can be modified to alter permeability or
porosity.
In the present study, we synthesized a core-shell particle in
which a N-isopropylacrylamide (NIPAm)-acrylic acid (AAc) core
Particles Preserve Biomarkers
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contains a charge based bait to perform affinity binding to proteins
in solutions, and a NIPAm shell surrounds the core and acts as a
sieve to exclude solution phase proteins too large to penetrate the
porosity of the shell (Fig. 2). NIPAm based particles exclude larger
molecules with a sharp molecular size cut off due to their porous
structure. The degree of porosity can be tuned by changing the
percentage of cross-linker N,N’methylenebisacrylamide (BIS) with
respect to the monomer. At the same time, particles can imbibe
large amounts of water which provide favorable conditions for
polypeptides and other small molecules to penetrate the polymer
matrix, and also allow concentration of rare protein biomarkers
[14].
We used three independent experimental systems to test
whether the new particles could accomplish the following a)
Rapidly harvest all of the solution phase PDGF and chemokine
molecules within a complex mixture of high abundance proteins
including whole serum, b) Release the captured PDGF and
chemokine into a small volume that was a fraction of the starting
volume, while completely excluding high abundance proteins such
as albumin. This concentration step has the potential to magnify
the detectable level of the marker in a small volume that is
required for input into a measurement system such as an
immunoassay platform or mass spectrometry, and c) Protect the
captured PDGF and chemokine from degradation by exogenous
degradative enzymes introduced at high concentration. The three
independent experimental approaches employed for the present
study were 1) A clinical grade ELISA immunoassay, 2) Gel
Electrophoresis of the starting solution, the supernatant and the
particle contents followed by immunoblotting, and 3) Mass
Spectrometry analysis of the starting solution compared to the
particle capture eluate.
The purpose of this study was to explore the capacity of the
core-shell particles to concentrate and preserve biomarkers as
theoretically envisioned.
Figure 1. Bait chemistry.
doi:10.1371/journal.pone.0004763.g001
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Results
Particle synthesis and characterization
For the particle architecture used in the present study, a NIPAm
shell surrounds a NIPAm/AAc core, containing affinity bait
moieties. The sieving capability of the NIPAm shell shields the core
and its affinity bait groups from larger molecules that may be present
and could compete with the intended low-abundance, low molecular
weight molecular targets for binding to the affinity bait in the core.
Light scattering characterization was conducted on the particles
during synthesis and at the end of the process in order to compare
the sizes of the core and the core-shell particles. The core diameter at
25uC and pH 4.5 is 364.7+/24.3 nm whereas the diameter of the
core-shell particles at the same conditions is 699.4+/26.2 nm
(Fig. 3A). This suggests that the thickness of the shell is about
170 nm. Following the characteristic behavior of AAc containing
hydrogels, both the core and the core-shell particle size decreased
with increasing temperature and decreasing pH (Fig. 3A). Particles
were further characterized by means of atomic force microscopy
(AFM). AFM particle images (Fig. 3B) confirm size homogeneity,
and AFM particle diameter readings were consistent with those
measured with light scattering. Particle concentration, as obtained by
weighing the lyophilized particles, was 10 mg/mL, and the number
of particles per milliliter was 230 million.
Molecular sieving and concentration of PDGF by core-
shell particles
Human platelet derived growth factor (PDGF, MW 14,500 Da)
was spiked in a solution containing bovine serum albumin (BSA,
MW 66,000 Da) as carrier protein associated with the PDGF.
Figure 2. Schematic illustration of core shell particle. The nanoparticle consists of a NIPAm-AAc core that functions as a bait. After adding
particles to the protein solution, biomarkers are attracted and entrapped in this bait. A NIPAm shell increases the sieving properties of nanoparticles.
doi:10.1371/journal.pone.0004763.g002
Figure 3. Light scattering and atomic force microscopy characterization of nanoparticles. (A) At room temperature, core is approximately
360 nm in size whereas adding core-shell particles have a diameter of 700 nm at pH 4.5. Core and core shell particles follow a typical temperature
dependent behavior. (B) Particle suspension in MilliQ water (pH 5.5, 1 mg/mL) was deposited on freshly cleaved mica under humid atmosphere at
room temperature for 15 minutes and dried under nitrogen. Atomic force microscopy (AFM) image of nanoparticles was acquired. Particles have a
diameter of approximately 800 nm and exhibit a homogeneous size distribution. The scale bar for particle height shows a maximum height of
168 nm. The AFM picture was acquired under dry status therefore the particles are distorted (flattened) from their spherical shape due to drying on
the mica surface.
doi:10.1371/journal.pone.0004763.g003
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Core-shell hydrogel nanoparticles added to the PDGF-BSA
solution acted as a molecular sieve as evidenced by no detectable
association of BSA with the particles, and the particles completely
sequestered all the solution phase PDGF while completely
excluding the BSA (Fig. 4A). This suggests that PDGF affinity
for the bait was higher than that for carrier BSA. In order to
further assess the molecular sieving properties of core-shell
particles, a solution containing: PDGF, BSA, aprotinin (MW
6,500 Da), lysozyme (MW 14,400 Da), trypsin inhibitor (MW
21,500 Da), carbonic anhydrase (MW 31,000 Da), and ovalbumin
(MW 45,000 Da), was used. The uptake of proteins by the
particles was evaluated by SDS PAGE. Core-shell particles
efficaciously captured and concentrated low molecular weight
proteins with a weight less than 21,500 Da whereas proteins with
high molecular weight remained excluded from the particles
(Fig 4B).
Concentration of PDGF in solution by core-shell hydrogel
nanoparticles
We examined the nanoparticles ability to concentrate a dilute
PDGF sample, at a concentration below the detection threshold of
the ELISA, to determine if the concentration of PDGF could be
increased by particle sequestration, rendering the PDGF measur-
able by the ELISA.
As shown in Fig. 5A, previously undetectable level of PDGF was
recovered from the particles and successfully quantified by ELISA
at concentrations ranging from 75 to 102 pg/mL. The value of
PDGF concentration in the starting solution (18.92+/24.313 pg/
mL) reported in Fig. 5A was below the linear range of the ELISA
immunoassay (minimum detectable PDGF dose = 30 pg/mL) and
was estimated by using the optical density and extrapolated from
the standard curve. Per manufacturer’s instructions, the minimum
detectable dose was determined by adding two standard deviations
to the mean optical density value of twenty zero standard
replicates and calculating the corresponding concentration.
Therefore, core-shell particles, incubated with a PDGF solution
at a concentration undetectable by ELISA, harvested and
concentrated PDGF to a level higher than the detection limit of
the assay. Saturation was reached with the minimum amount of
particles when the PDGF solution was very dilute, as expected
(Fig. 5B). A standard curve for PDGF ELISA assay was generated
(Fig. 5C) in order to assess the quality of the procedure. A similar
experiment was performed with a more concentrated PDGF
solution. The concentration of PDGF in the starting solution was
63.69 (+/21.448) pg/mL whereas the concentration of PDGF
recovered from particles was 452.81 (+/24.818) pg/mL yielding a
concentration factor of about 700% (Fig. 6A). A PDGF solution
was incubated with different volumes of particles and demonstrat-
ed that saturation was reached when the volume of particles was
200 ml (46 million particles, 1:5 v/v particles:PDGF solution ratio,
Fig. 6B). The standard curve for PDGF ELISA assay was repeated
(Fig. 6C).
A further experiment was performed in order to test the ability
of core shell particles to sequester, concentrate and preserve native
PDGF from human serum. We examined the effect of excess
interfering proteins on the amount of particles necessary to reach
saturation and complete depletion of native PDGF from serum.
Serum was diluted 1:10 in Tris HCl 50 mM pH 7 and incubated
with increasing quantities of particles (200, 500, 1000, and
1500 mL). The value of PDGF in the starting serum solution
was read as 170.92+/24.66 pg/mL whereas the concentration of
PDGF recovered from particles was 1743.43+/211.06 pg/mL
yielding a concentration factor of about 10-fold (1000 percent)
(Fig. 7A). Saturation was reached at a value of 1000 mL (230
million particles, 1:1 v/v particles:serum solution, Fig. 7B). Given
the fact that the starting concentration of PDGF in serum is higher
than the concentration of PDGF in the solution of Fig. 6, we can
conclude that the presence of serum, with its enormous protein
content in the starting sample, requires less than double amount of
particles to deplete the sample, thus confirming the extremely high
binding capacity of particles, even in the presence of abundant
serum proteins. The standard curve for the PDGF ELISA assay
used in these studies is shown (Fig. 7C).
Concentration of chemokines in solution by core-shell
particles
In Fig. 8 SDS PAGE analysis is shown on core shell acrylic acid
functionalized particles incubated with other relevant models for
serological biomarker, namely mucosae-associated epithelial
chemokine (MEC/CCL28, 12,300 Da), stromal cell-derived
factor-1 beta, (SDF-1b/CXCL12b, 8,500 Da), and eotaxin-2
(CCL24, 8,800 Da) mixed with BSA. Chemokines were totally
removed from solution, captured and concentrated by particles,
whereas BSA was completely excluded.
Protection from enzymatic degradation of PDGF by core-
shell particles
Degradation of biomarkers by endogenous and exogenous
proteases is a major source of biomarker performance bias, and
hinders the discovery and measurement of candidate biomarkers.
Immunoblot analysis was used to evaluate the particles ability to
protect PDGF from enzymatic degradation. Trypsin action on
PDGF in the absence of particles was evident after 10 minutes and
almost complete after one hour, as indicated by nearly
undetectable PDGF bands at 14,000–17,000 Da (Fig. 9A and
Fig. 9B Lanes 6–8). In marked contrast, PDGF incubated with
trypsin and core-shell particles generated a single species band that
was not diminished in staining intensity and was not fragmented,
Figure 4. SDS-PAGE Analysis of PDGF incubated particles. (A)
Lane 1) Starting solution containing BSA and PDGF (Control), 2)
Supernatant (OUT); 3) Particle content (IN). Particles remove PDGF from
carrier albumin with a total exclusion of albumin itself. (B) Lane 1)
Starting solution containing PDGF, BSA, aprotinin (MW 6,500 Da),
lysozyme (MW 14,400 Da), trypsin inhibitor (MW 21,500 Da), carbonic
anhydrase (MW 31,000 Da), and ovalbumin (MW 45,000 Da) (Control), 2)
Supernatant (OUT); 3) Particle content (IN). Particles harvest PDGF
together with low molecular weight proteins and exclude proteins
above ca 20,000 Da.
doi:10.1371/journal.pone.0004763.g004
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Figure 5. Core shell particles raise the concentration of undetectable PDGF into the detection range of ELISA assay. (A) ELISA readings
of the starting solution of PDGF in Calibrator diluent RD6-3 (R&D Systems, animal serum with preservatives) at a concentration of 18.92+/24.313 pg/
mL and PDGF eluted from core-shell particles (85.27+/22.24 pg/mL). (B) PDGF concentration in the core-shell particle eluate plotted against the
quantity of particles utilized for the incubation, duplicate experiments. (C) ELISA standard curve of PDGF concentration versus absorbance. The
standard curve was generated with two repeats for each PDGF calibrator concentration.
doi:10.1371/journal.pone.0004763.g005
Figure 6. Core shell particles increase the concentration of extremely dilute PDGF approximately 10-folds (1000 percent) as
measured by ELISA assay. (A) ELISA readings of the starting solution of PDGF in Calibrator diluent RD6-3 (R&D Systems, animal serum with
preservatives) at a concentration of 63.69+/21.448 pg/mL and PDGF eluted from core-shell particles (491.14+/24.818 pg/mL). (B) PDGF
concentration in core-shell particle eluate plotted against the quantity of particles utilized for the incubation, duplicate experiments. (C) ELISA
standard curve of PDGF concentration versus absorbance. The standard curve was generated with two repeats for each PDGF calibrator
concentration.
doi:10.1371/journal.pone.0004763.g006
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suggesting that particles successfully preserved PDGF from
proteolysis (Fig. 9A and Fig. 9B Lane 4). The PDGF band for
the particles loaded with PDGF without trypsin (Fig. 9A and
Fig. 9B Lane 2) was identical to that for the particles loaded with
PDGF and trypsin (Fig. 9A and Fig. 9B Lane 4) further suggesting
that no PDGF protein was lost because of enzymatic degradation.
Protection from enzymatic degradation of chemokines
by core-shell particles
SDS-PAGE analysis was used to evaluate the particles ability
to protect chemokines, chosen as model, from enzymatic
degradation. As shown in Fig. 10, trypsin rapidly degraded each
class of chemokines in the absence of the sequestration by
particles (Fig. 10, Lanes 2, 5, 8). In marked contrast, chemokines
incubated with trypsin and particles (Fig. 10, Lane 3, 6, 9)
generated a single species band that was not fragmented,
suggesting that particles successfully preserved biomarkers from
proteolysis.
Core-shell particles concentrate and preserve PDGF
spiked in human serum
The extremely short half-life of PDGF in plasma (2 minutes) is
a major analytical challenge. Immunoblotting and mass
spectrometry were used to study the efficiency of core-shell
particles to harvest, concentrate and preserve PDGF spiked in
human serum. Immunoblotting was used to verify the preserva-
tion of PDGF by the presence of the correct molecular weight
intact protein.
Aliquots of 50 mL of core-shell particles were incubated with
50 mL of a solution with PDGF (at a concentration of 5 ng/mL
or 2 ng/mL) spiked in human serum diluted 1:25 in 50 mM
TrisHCl pH 7 for 1 hour at room temperature. The particles
excluded the high molecular weight proteins which remained in
the supernatant (Fig. 11, Lane 2 and 5) and at the same time
concentrated PDGF (Fig. 11, Lane 3 and Lane 6) that was
Figure 7. Core shell particles increase the concentration of native PDGF in serum as measured by ELISA assay. (A) ELISA readings of
the starting serum solution in Calibrator diluent RD6-3 (R&D Systems, animal serum with preservatives) at a concentration of 170.91+/24.66 pg/mL
and PDGF eluted from core-shell particles (1743.43+/211.06 pg/mL). (B) PDGF concentration in core-shell particle eluate plotted against the quantity
of particles utilized for the incubation, duplicate experiments. (C) ELISA standard curve of PDGF concentration versus absorbance. The standard curve
was generated with two repeats for each PDGF calibrator concentration.
doi:10.1371/journal.pone.0004763.g007
Figure 8. SDS PAGE analysis showing chemokines uptake by
particles. Core-shell particles were incubated with the following
chemokines, mucosae-associated epithelial chemokine (MEC/CCL28),
stromal cell-derived factor-1 beta, (SDF-1b/CXCL12b), and eotaxin-2
(CCL24), in presence of bovine serum albumin (BSA). Solutions of the
chemokines and BSA are shown in lanes 1, 4, and 7. After incubation
with the particles, no chemokine was left in the supernatant (S, lane 2,
5, and 8) and all the chemokine was captured by particles (P, lanes 3, 6,
and 9). BSA was totally excluded by particles.
doi:10.1371/journal.pone.0004763.g008
Particles Preserve Biomarkers
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spiked in serum at two different concentrations. As shown above
with the ELISA, PDGF in the starting solution was undetectable
(Fig. 11, Lane 1 and 4). The particles increased the
concentration of PDGF well above the immunoblot detection
limit within an extraordinarily complex serum solution, with no
detectable alteration in the mass or abundance of the PDGF
molecule.
Application of core-shell particles to preanalytical sample
preparation prior to mass spectrometry analysis of
complex protein mixtures
Mass spectrometers have a detection sensitivity two to three
orders of magnitude above the concentration of low abundance
serum proteins which are expected to provide the most valuable
diagnostic information. Mass spectrometry analysis demonstrated
that core-shell particles are able to concentrate and preserve
PDGF in known protein mixtures and in serum.
As shown in Table 1, mass spectrometry analysis of the solutions
containing PDGF at a ratio of 1:60, 1:600 and 1:6,000 to total
protein identified 13, 6, and 1 peptides belonging to human PDGF
respectively, while eluates from core-shell particles contained 33,
Figure 9. Immunoblot analysis showing that core-shell parti-
cles protect captured PDGF from tryptic degradation. (A) Sypro
ruby total protein staining and (B) Immunoblot analysis with anti-PDGF
antibody of the same PVDF membrane are presented. Lane 1) control
PDGF+BSA solution; 2) content of particles incubated with PDGF+BSA
(IN); 3) supernatant of particles incubated with PDGF+BSA (OUT); 4)
content of particles incubated with BSA+PDGF+trypsin (IN+TRYPSIN); 5)
supernatant of particles incubated with BSA+PDGF+trypsin (OUT+-
TRYPSIN); 6) BSA+PDGF+trypsin without particles incubated for
40 minutes (+TRYPSIN 409); 7)) BSA+PDGF+trypsin without particles
incubated for 20 minutes (+TRYPSIN 209); 8)) BSA+PDGF+trypsin
without particles incubated for 10 minutes (+TRYPSIN 109); 9))
BSA+PDGF+trypsin without particles incubated for 0 minutes (+TRYP-
SIN 09).
doi:10.1371/journal.pone.0004763.g009
Figure 10. SDS PAGE analysis showing that core-shell particles
protect chemokines from enzymatic degradation. Core-shell
particles were incubated with the following chemokines, mucosae-
associated epithelial chemokine (MEC/CCL28), stromal cell-derived
factor-1 beta, (SDF-1b/CXCL12b), and eotaxin-2 (CCL24), in presence
of trypsin. Solution of the chemokines (control) are shown in Lanes 1, 4,
and 7. Chemokines incubated with particles (Lane 3, 6, and 9) are
protected from tryptic degradation whereas chemokines not incubated
with particles (Lane 2, 5, and 8) are susceptible to proteolytic digestion.
doi:10.1371/journal.pone.0004763.g010
Figure 11. Immunoblot analysis demonstrating recovery of
PDGF spiked in human serum. Lane 1) Human serum plus PDGF
(5 ng/mL): when serum is not incubated with particles, PDGF cannot be
detected; 2) particle supernatant (OUT); 3) particle content (IN); 4)
Human serum plus PDGF (2 ng/mL): when serum is not incubated with
particles, PDGF cannot be detected; 2) particle supernatant (OUT); 3)
particle content (IN).
doi:10.1371/journal.pone.0004763.g011
Particles Preserve Biomarkers
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Table 1. Comparison of identified tryptic peptides from particle elute and starting solution by nano reverse phase liquid
chromatography mass spectrometry (RPLC-MS/MS).
Dilution
PDGF
concentration
(ng/ml)
Identified tryptic
peptides from
Particle Elute a
Peptide
Ions b
Peptide
Hits c
Identified tryptic
peptides from
Starting Solution a
Peptide
Ions b
Peptide
Hitsc
1:60 667 K.KATVTLEDHLACK.C 18/24 33 K.KATVTLEDHLACK.C 17/24 13
K.KATVTLEDHLACK.C 18/24 K.KATVTLEDHLACK.C 18/24
K.ATVTLEDHLACK.C 16/22 K.ATVTLEDHLACK.C 16/22
K.KATVTLEDHLACK.C 19/24 K.TRTEVFEISR.R 16/18
K.KATVTLEDHLACK.C 27/48 K.TRTEVFEISR.R 15/18
K.KATVTLEDHLACK.C 18/24 K.ATVTLEDHLACK.C 17/22
K.TRTEVFEISRR.L 13/20 K.TRTEVFEISR.R 16/18
K.ATVTLEDHLACK.C 16/22 K.TRTEVFEISR.R 22/36
K.TRTEVFEISR.R 17/18 R.TEVFEISR.R 13/14
K.ATVTLEDHLACK.C 17/22 R.SLGSLTIAEPAMIAECK.T 21/32
K.ATVTLEDHLACK.C 15/22 R.TNANFLVWPPCVEVQR.C 19/30
K.TRTEVFEISR.R 15/18 R.TNANFLVWPPCVEVQR.CR.
TNANFLVWPPCVEVQR.C
22/30
K.ATVTLEDHLACK.C 17/22 22/30
R.NVQCRPTQVQLRPVQVR.K 26/64
K.TRTEVFEISR.R 16/18
K.TRTEVFEISR.R 23/36
K.ATVTLEDHLACK.C 14/22
K.TRTEVFEISR.R 17/18
K.ATVTLEDHLACKCETVAAAR.P 34/76
R.TEVFEISR.R 13/14
R.SLGSLTIAEPAMIAECK.T 15/32
R.SLGSLTIAEPAMIAECK.T 21/32
R.SLGSLTIAEPAMIAECK.T 41/64
R.TNANFLVWPPCVEVQR.C 18/30
R.TNANFLVWPPCVEVQR.C 22/30
R.LIDRTNANFLVWPPCVEVQR.C 32/76
R.TNANFLVWPPCVEVQR.C 23/30
R.TNANFLVWPPCVEVQR.C 23/30
R.TNANFLVWPPCVEVQR.C 17/30
R.TNANFLVWPPCVEVQR.C 13/30
R.TNANFLVWPPCVEVQR.C 15/30
R.TNANFLVWPPCVEVQR.C 14/30
R.TNANFLVWPPCVEVQR.C 16/30
1:600 66.7 K.KATVTLEDHLACK.C 19/24 15 K.KATVTLEDHLACK.C 18/24 6
K.ATVTLEDHLACK.C 13/22 R.NVQCRPTQVQLRPVQVR.K 26/64
K.KATVTLEDHLACK.C 19/24 K.TRTEVFEISR.R 15/18
K.ATVTLEDHLACK.C 16/22 R.TEVFEISR.R 13/14
K.ATVTLEDHLACK.C 14/22 R.TNANFLVWPPCVEVQR.CR.
TNANFLVWPPCVEVQR.C
16/30
K.TRTEVFEISR.R 16/18 20/30
K.ATVTLEDHLACK.C 16/22
R.NVQCRPTQVQLRPVQVR.K 28/64
K.TRTEVFEISR.R 15/18
R.TEVFEISR.R 13/14
R.SLGSLTIAEPAMIAECK.T 21/32
R.TNANFLVWPPCVEVQR.C 19/30
R.TNANFLVWPPCVEVQR.C 19/30
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15, 5 peptides respectively. At 1:60,000 PDGF to total protein
ratio, PDGF peptides were not detected in the original solution
after trypsin digestion for mass spectrometric analysis (PDGF
concentration of 0.67 ng/mL), while eluates from the particles
yielded a clear mass spectrometer detection spectra of the PDGF
trypsin peptides. Thus core-shell particles increased the number of
peptides, identified by mass spectrometry, from a solution when
PDGF was present within the known detection level of the mass
spectrometer. In addition, when this biomarker was diluted to less
than one nanogram per mL and was masked by highly abundant
proteins, the core-shell particles were able to concentrate PDGF
and raise it into the detection range of mass spectrometry.
In order to further assess the capability of particles to
concentrate and preserve PDGF in a physiologic medium, and
to identify any proteins sequestered simultaneously, PDGF (at a
concentration of 5 ng/mL) was spiked in human serum diluted
1:25 in 50 mM TrisHCl pH 7 and the solution was incubated with
50 ml of core-shell particles for 1 hour. Proteins were eluted, dried
and analyzed with nanoRPLC-MS/MS. As shown in Table S1,
PDGF was recovered and clearly identified with high peptide hit
coverage by mass spectrometer analysis. A number of rare and low
molecular weight proteins were identified, within the mixture of
proteins captured by the core-shell particles. Additionally, core-
shell particles were incubated with human serum and the proteins
eluted from the particles were analyzed with nanoRPLC-MS/MS.
Peptides belonging to native PDGF present in blood at very low
abundance (,1 ng/mL) were identified. Examples of identified
rare proteins are reported in Table 2.
These data support the use of the core-shell particles to harvest
and preserve known biomarkers from serum, while providing a
means to dramatically increase the concentration of biomarkers
and the effective sensitivity of current biomarker measurement and
discovery technology.
Discussion
(NIPAm/AAc)core–(NIPAm)shell hydrogel particles have been
synthesized and successfully applied to harvest, concentrate, and
protect from degradation, PDGF and various chemokines, low
abundance labile clinical biomarkers from model solutions and
serum, a known complex biologic fluid targeted for biomarker
discovery. These functions were studied using three independent
experimental systems: a quantitative highly sensitive immunoassay,
immunoblotting, and mass spectrometry. PDGF and chemokines,
chosen as model clinical biomarker analytes, was completely
separated from carrier albumin, concentrated, and fully preserved,
within minutes, when spiked in model solutions and in human
serum. Particle sequestered PDGF and chemokines were fully
protected from exogenously added tryptic degradation. Starting with
a dilute non detectable concentration of PDGF in the starting
solution, the particles partially purified and concentrated this analyte
by several orders of magnitude (depending on the starting volume
versus the elution volume ratio) into a smaller volume, thereby
bringing it into the detection range of a clinical grade PDGF ELISA.
Hydrogel core-shell particles harvested and concentrated dilute
PDGF along with other low abundance proteins from a complex
mixture of high abundance proteins to constitute a new preanalytical
method for mass spectrometer based biomarker discovery. The
concentration step afforded by the particles appeared to significantly
increase the yield of detectable mass spectrometry peptides greater
than ten fold compared to direct analysis of the starting solution by
conventional sample prep methods.
A major source of biomarker measurement bias and variability
is the degradation of biomarkers within the blood sample
immediately after venipuncture and during shipment and storage.
We envision the application of harvesting core-shell nanoparticles
to whole blood for concentration and immediate preservation of
low abundance and labile analytes at the time of venipuncture.
Accordingly we have tested the use of lyophilized nanoparticles
pre-loaded into blood collection vacutainers. Because of the
relative small size and mass of the particles, whole blood
containing nanoparticles can be centrifuged to remove the blood
cells while leaving the nanoparticles in solution for subsequent
collection and elution of their contents.
Hydrogel based core-shell particles can be produced in large
quantities at low cost, are very reproducible and very uniform in
size (diameter,700 nanometers); particles are stable at room
temperature indefinitely.
Nanoparticle harvesting has applications to the proteomic
analysis of body fluids beyond blood, such as urine [37],
cerebrospinal fluid, and amniotic fluid, which are promising
biologic sources for biomarker discovery and measurements
Dilution
PDGF
concentration
(ng/ml)
Identified tryptic
peptides from
Particle Elute a
Peptide
Ions b
Peptide
Hits c
Identified tryptic
peptides from
Starting Solution a
Peptide
Ions b
Peptide
Hitsc
R.TNANFLVWPPCVEVQR.C 21/30
R.TNANFLVWPPCVEVQR.C 21/30
1:6,000 6.67 K.ATVTLEDHLACK.C 16/22 5 R.NVQCRPTQVQLRPVQVR.K 24/64 1
R.NVQCRPTQVQLRPVQVR.K 27/64
K.TRTEVFEISR.R 15/18
R.TNANFLVWPPCVEVQR.C 14/30
R.TNANFLVWPPCVEVQR.C 20/30
1:60,000 0.667 K.ATVTLEDHLACK.C 13/22 1 PDGF was not detected 0
aThe amino acids between the dots are the identified tryptic peptide sequence, and the amino acid before or after the dot is the upstream or downstream residue of
this peptide.
bPeptide Ions is the ratio of number of matched b-ions and y-ions to the number of theoretical b-ions and y-ions for the identified peptide based on Sequest database
search result.
cPeptide Hits is the total number of identified peptides (including the same peptide with the same charge, the same peptide with different charge, and the different
peptide) from one protein based on Sequest database search result.
doi:10.1371/journal.pone.0004763.t001
Table 1. Cont.
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[52,53]. We have created a variety of core baits which have affinity
for proteins, peptides, phosphoproteins, glycoprotein’s, metabo-
lites, and nucleic acids. Thus it is realistic to propose the use of a
mixture of nanoparticles containing subpopulations specifically
designed to target a separate class of analyte. In this way,
harvesting nanoparticles can be applied to the multiplex analysis of
a panel of analytes within a single fluid sample.
Materials and Methods
The serum used in this study was obtained under an IRB
approved serum collection protocol (protocol number GMU
HSRB #6081) under informed consent and the data were
analyzed anonymously in compliance with HIPAA and the
principles expressed in the Declaration of Helsinki.
Table 2. Native PDGF was found in healthy donor serum purified by core shell particles and measured by nano reverse phase
liquid chromatography mass spectrometry (RPLC-MS/MS).
Reference Accessiona Ppep
b Sf
c Scored MWe ePeptide
properdin P factor, complement 4505737 2.22E-15 4.56 50.27 51242.0 6
vinculin isoform meta-VCL 7669550 5.55E-15 11.49 130.23 123721.9 13
talin 1 16753233 1.22E-14 32.50 350.29 269497.3 38
angiogenin, ribonuclease, RNase A family, 5 precursor 4557313 2.70E-13 6.45 70.24 16539.4 10
serum amyloid A4, constitutive 10835095 4.89E-12 2.89 30.26 14797.3 4
serum deprivation response protein 4759082 3.23E-10 1.85 20.22 47144.6 2
peroxiredoxin 6 4758638 4.14E-09 0.90 10.20 25019.2 1
glyceraldehyde-3-phosphate dehydrogenase 7669492 2.26E-08 1.66 20.19 36030.4 2
tissue inhibitor of metalloproteinase 3 precursor 4507513 2.57E-08 1.88 20.17 24128.8 2
parvin, beta isoform b 20127528 4.09E-08 0.96 10.17 41688.1 1
chemokine (C-C motif) ligand 28 22538811 7.08E-08 0.98 10.22 14270.4 1
talin 2 22035665 8.11E-08 1.52 20.16 271382.8 2
S100 calcium-binding protein A9 4506773 1.05E-07 0.95 10.20 13233.5 1
ras suppressor protein 1 isoform 2 34577083 2.56E-07 1.76 20.25 25529.6 2
serum amyloid P component precursor 4502133 3.33E-07 1.86 20.15 25371.1 2
tubulin, alpha, ubiquitous 57013276 4.45E-07 2.67 30.17 50119.6 3
chemokine (C-X-C motif) ligand 12 76563933 6.29E-07 2.73 30.21 13696.7 3
enolase 1 4503571 7.04E-07 0.80 10.15 47139.4 1
cathelicidin antimicrobial peptide 39753970 1.08E-06 0.90 10.13 19289.2 1
cell division cycle 42 isoform 1 89903012 1.37E-06 0.94 10.16 21245.0 1
cardiac muscle alpha actin proprotein 4885049 1.59E-06 4.25 50.21 41991.9 5
PREDICTED: similar to ARP3 actin-related protein 3 homolog B 113419329 1.79E-06 0.95 10.15 43634.8 1
brain-derived neurotrophic factor isoform a preproprotein 25306253 2.20E-06 1.87 20.19 27800.0 2
brain-derived neurotrophic factor isoform c preproprotein 25306261 2.20E-06 1.87 20.19 29798.0 2
PREDICTED: similar to Prostate, ovary, testis expressed protein on chromosome 2 113413194 4.56E-06 3.09 40.17 121366.6 4
defensin, alpha 1 preproprotein 4758146 5.92E-06 0.91 10.15 10194.2 2
defensin, alpha 3 preproprotein 4885179 5.92E-06 0.91 10.15 10238.2 2
small inducible cytokine A24 22165427 6.03E-06 0.93 10.14 13124.8 1
villin 2 21614499 9.13E-06 0.92 10.14 69369.8 1
radixin 4506467 9.13E-06 0.92 10.14 68521.5 1
platelet-derived growth factor beta isoform 1, preproprotein 4505681 1.75E-05 0.91 10.15 27266.1 1
platelet-derived growth factor beta isoform 2, preproprotein 15451786 1.75E-05 0.91 10.15 25486.2 1
kininogen 1 4504893 1.81E-05 1.77 20.19 47852.7 2
S100 calcium-binding protein A8 21614544 2.03E-05 0.93 10.16 10827.7 1
transgelin 2 4507357 1.06E-04 0.88 10.14 22377.2 1
ras-related GTP-binding protein 33695095 1.50E-04 0.93 10.13 22454.6 1
vitamin D-binding protein precursor 32483410 6.18E-04 0.87 10.18 52883.0 1
a‘‘Accession’’ displays the unique protein identification number for the sequence.
b‘‘Ppep’’ displays the probability value for the peptide.
c‘‘Sf’’ displays the final score that indicates how good the protein match is.
d‘‘score’’ displays a value that is based upon the probability that the peptide is a random match to the spectral data.
e‘‘Peptide’’ displays the total number peptide matches.
doi:10.1371/journal.pone.0004763.t002
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Synthesis of core-shell hydrogel particles
Particles were synthesized using NIPAm (Sigma-Aldrich) and
BIS (Sigma-Aldrich) by precipitation polymerization [49]. AAc
(Sigma-Aldrich) was incorporated into NIPAm particle to provide
a charge based affinity moiety bait for affinity capture of peptides
and small molecules [9].
(NIPAm/AAc) core
NIPAm (0.184 g), BIS (0.0055 g), and AAc (48.4 mL) were
dissolved in 30 mL of H2O and then passed through a 0.2 mm
filter. The solution was purged with nitrogen for 15 min at room
temperature and medium stir rate and then heated to 70uC.
Ammonium persulfate (APS, Sigma-Aldrich, 0.0099 g) in 1 mL of
H2O was added to the solution to initiate polymerization. After
10 minutes shell solution was added.
(NIPAm)shell
The shell solution was prepared by dissolving 0.736 g of NIPAm
and 0.120 g of BIS in 10 ml of water. The solution was passed
through a 0.2 mm filter and purged with nitrogen for 15 min at
room temperature and medium stir rate. After 10 minutes from
APS injection, shell solution was added to the reacting core
solution. The reaction was maintained at 70uC under nitrogen for
3 h and then cooled overnight. Particles were washed to eliminate
un-reacted monomer by subsequent centrifugations at 16.1 rcf,
25uC, 15 minutes. Supernatant was disposed and particles re-
suspended in 1 ml of water.
Characterization of Particles
The concentration of particles was assessed by weighing the
lyophilized particles. Particles were counted by flow cytometry.
Particle size dependence on temperature and pH was
determined via photon correlation spectroscopy (submicron
particle size analyzer, Beckman Coulter). The pH of solution
was controlled by adding proper amounts of NaOH, HCl with
background electrolyte solution of KCl. Average values were
calculated for three measurements using a 200 s integration time,
and the solutions were allowed to thermally equilibrate for 10 min
before each set of measurements. Measured values were then
converted to particle sizes via the Stokes-Einstein relationship [54].
Particles were further characterized by atomic force microscopy
(AFM) using an NSCRIPTORTM DPNH System (NanoInk).
Particle suspension in MilliQ water (pH 5.5, 1 mg/mL) was
deposited on freshly cleaved mica under humid atmosphere at
room temperature for 15 minutes and dried under nitrogen before
measurement. Images were acquired under AC mode using a
silicon tip with a typical resonance frequency of 300 kHz and a
radius smaller than 10 nm.
Particle incubation
50 mL of core-shell particles were incubated with 50 mL of
solution containing:
– 0.02 mg/mL PDGF, 0.2 mg/mL BSA in 50 mM TrisHCl
pH 7;
– PDGF, BSA, aprotinin (MW 6,500 Da), lysozyme (MW
14,400 Da), trypsin inhibitor (MW 21,500 Da), carbonic
anhydrase (MW 31,000 Da), and ovalbumin (MW
45,000 Da), each at a concentration of 0.05 mg/mL dissolved
in 50 mM Tris pH 7.
– mucosae-associated epithelial chemokine (MEC/CCL28, Anti-
genix America), stromal cell-derived factor-1 beta, (SDF-1b/
CXCL12b, Antigenix America), and eotaxin-2 (CCL24,
Antigenix America) each at a concentration of 0.02 mg/mL
mixed with BSA (0.2 mg/mL) and dissolved in 50 mM Tris
pH 7.
Incubations lasted 30 minutes at room temperature. After
incubation, samples were centrifuged for 7 minutes, 25uC at 16,1
rcf and supernatant was saved. Then, the particles were re-
suspended in 1 mL water and centrifuged for 7 minutes, 25uC at
16,1 rcf. Centrifugation and washing were repeated three times.
Particle elution of captured analytes
The particles were directly loaded on the gel when performing
SDS-PAGE or immunoblot analysis. When performing ELISA
and mass spectrometry analysis washed particles were incubated
with elution buffer (60% acetonitrile-2% acetic acid) for
30 minutes and then centrifuged for 7 minutes, 25uC at 16,1 rcf.
Eluate was saved, a second elution step was performed and the
eluate saved in the same vial. Samples were then dried with Speed
Vac (ThermoFisher) and analyzed with ELISA or mass spectrom-
etry.
SDS-PAGE analysis
Particles and supernatant deriving from particle incubation
were loaded on 18% Tris Glycine gel (Invitrogen Corporation).
The particles were retained in the stacking region of the gel while
all of the captured proteins were electroeluted from particles and
resolved in the gel. Proteins were detected by silver staining.
Enzymatic Degradation analysis
PDGF-BSA (Cell Signaling Technology) solution (0.11 mg/mL
total protein) in 50 mM TrisHCl pH 7 was incubated with trypsin
(Promega Corporation) at 1:100 w/w protein:protease ratio for
different time periods (0, 10, 20, and 40 minutes) at 37uC in order
to study the degradation patterns over time. Core-shell particles
were incubated for 1 hour at 37uC in a 50 mM TrisHCl pH 7
solution containing PDGF-BSA (0.11 mg/mL total protein) and
trypsin (0.0011 mg/mL).
Each of the following chemokines MEC/CCL28, SDF-1b/
CXCL12b, CCL24 dissolved in 50 mM TrisHCl pH 7 at a
concentration of 0.02 mg/mL was incubated separately with
trypsin at 1:50 w/w protein:protease ratio and with core-shell
particles for 40 minutes at 37uC.
Immunoblot analysis
Proteins were separated by 1-D gel electrophoresis in 18% Tris-
Glycine gel as before, and then transferred onto Immobilion
PVDF membrane (Millipore). The membrane was stained with
SYPRO Ruby stain (MolecularProbes) according to vendor
instructions. The protein blot was imaged using Kodak
4000 MM. The membrane was then incubated with PBS
supplemented with 0.2% I-Block (Applied Biosystems/Tropix)
and 0.1% Tween 20 (Sigma-Aldrich) for 1 hour at room
temperature, and then with antibody raised against PDGF-BB
overnight at 4uC under continuous agitation. After washes with
PBS supplemented with 0.2% I-Block (w/v) and 0.1% Tween 20,
immunoreactivity was revealed by using a specific horseradish
peroxidase conjugated anti-IgG secondary antibody and the
enhanced chemiluminescence system (Supersignal West Dura,
ThermoFisher Scientific).
ELISA analysis
Particles were incubated with 1 mL of PDGF-BB standard
(R&D System) diluted in Calibrator Diluent RD6-3. Incubation
times, washings, and elutions were carried out as previously
Particles Preserve Biomarkers
PLoS ONE | www.plosone.org 12 March 2009 | Volume 4 | Issue 3 | e4763
described. Eluate dried with Speed Vac was re-suspended in
100 mL of water with gentle vortexing and then an ELISA assay
for Human PDGF-BB was performed according to manufacturer’s
instructions. Each measurement was carried out in duplicate and
individual standard curves were generated for each set of samples
assayed. Aliquots of 1 mL of PDGF solution below the detection
limit of the kit (20 pg/mL) were incubated for 30 minutes with
different numbers of particles (50, 100, 200, and 500 ml). Proteins
were eluted from the washed particles by means of two subsequent
elution steps with 60% acetonitrile and 2% acetic acid. ELISA
readings were performed on a volume of 100 mL.
ELISA measurement of native serum PDGF was used to judge the
particle capture yield for a series of particle concentrations introduced
in serum. Aliquots of 1000 mL of serum diluted 1:10 in 50 mM Tris
HCl pH were incubated with increasing quantities of particles (200,
500, 1000, and 1500 mL) for 30 minutes at room temperature.
Particles were washed as previously described and incubated with
100 mL of elution buffer (60% acetonitrile-2% acetic acid) for
10 minutes and then centrifuged (7 minutes, 25uC at 16.1 rcf).
Particle eluates were freeze dried and resuspended in Calibrator
Diluent RD6-3, R&D Systems. Serum solution was diluted in
Calibrator Diluent. ELISA readings were performed on a volume of
100 mL.
Mass spectrometry analysis
The following solutions were incubated with the core-shell
particles:
– PDGF spiked in complex protein mixture: a protein mixture
containing 6.7 mg/mL BSA (ThermoFisher Scientific, MW
66,000), 6.7 mg/mL aprotinin (Sigma-Aldrich, MW 6,500 Da),
6.7 mg/mL lysozyme (Sigma-Aldrich, MW 14,400 Da),
6.7 mg/mL trypsin inhibitor (Invitrogen Corporation, MW
21,500 Da), 6.7 mg/mL carbonic anhydrase (Sigma-Aldrich,
MW 31,000 Da), and 6.7 mg/mL ovalbumin (Sigma-Aldrich,
MW 45,000 Da) in 50 mM TrisHCl pH 7 with a total protein
concentration of 40 mg/mL was used. PDGF was added at the
following concentrations: 670 ng/mL, 67 ng/mL, 6.7 ng/mL,
0.67 ng/mL so that the ratio between PDGF and the total
protein was 1:60, 1:600, 1:6,000 and 1:60,000 respectively.
Aliquots of 1.5 mL of solution were incubated with 100 mL of
core-shell particles. Proteins were eluted with 60% acetonitrile
and 2% acetic acid in a volume of 100 mL, eluates were dried
with a Speed Vac (Thermo) and analyzed with nano reverse
phase liquid chromatography mass spectrometry (RPLC-MS/
MS). Aliquots of 100 mL were analyzed both from solution and
eluates, thus maintaining the same volume.
– human serum: 200 mL of healthy donor serum was diluted 1:3 in
TrisHCl buffer, pH 7 50 mM, with 100 mL of core-shell
particles. Particles were washed with 10% acetonitrile,
0.56PBS buffer, and eluted with acetonitrile 60%, acetic acid
2%. Sample was dried with Speed Vac (Thermo) and analysed
with nanoRPLC-MS/MS.
Eluates from the particles were analyzed with nanoRPLC-MS/
MS. Proteins dried with Speed Vac were reconstituted in 8 M urea,
reduced by 10 mM DTT, alkylated by 50 mM iodoacetamide, and
digested by trypsin at 37uC overnight. Tryptic peptides were further
purified by Zip-Tip (Millipore) and analyzed by LC-MS/MS using a
linear ion-trap mass spectrometer (LTQ, Orbitrap). After sample
injection, the column was washed for 5 minutes with mobile phase A
(0.4% acetic acid) and peptides eluted using a linear gradient of 0%
mobile phase B (0.4% acetic acid, 80% acetonitrile) to 50% mobile
phase B in 30 minutes at 250 nanoliter/min, then to 100% mobile
phase B for an additional 5 minutes. The LTQ mass spectrometer
was operated in a data-dependent mode in which each full MS scan
was followed by five MS/MS scans where the five most abundant
molecular ions were dynamically selected for collision-induced
dissociation (CID) using a normalized collision energy of 35%.
Tandem mass spectra were searched against SEQUEST database
using tryptic cleavage constraints. High-confidence peptide identifi-
cations were obtained by applying the following filters to the search
results: cross-correlation score (XCorr).=1.9 for 1+, 2.2 for 2+, 3.5
for 3+, and a maximum probability for a random identification of
0.01.
Supporting Information
Table S1 Concentration of PDGF spiked in human serum by
core-shell particles. Mass spectrometry analysis of proteins eluted
from core shell particles incubated with human serum containing
PDGF spiked at a concentration of 5 ng/mL.
Found at: doi:10.1371/journal.pone.0004763.s001 (0.03 MB
XLS)
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